Cubist Systematic Strategies’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Cubist Systematic Strategies’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-10,455	Closed	-$247K	–	2640
2019 Q3	$247K	Buy	10,455 +8,665	+484%	+$257K	﹤0.01%	1661
2019 Q2	$54K	Sell	1,790 -23,111	-93%	-$529K	﹤0.01%	2317
2019 Q1	$558K	Buy	+24,901	New	+$535K	0.02%	1118
2018 Q4	–	Sell	-208	Closed	-$4K	–	2392
2018 Q3	$4K	Buy	+208	New	+$2.46K	﹤0.01%	1843
2018 Q2	–	Sell	-19,999	Closed	-$106K	–	2177
2018 Q1	$106K	Buy	19,999 +17,820	+818%	+$127K	0.01%	1582
2017 Q4	$19K	Buy	+2,179	New	+$26.8K	﹤0.01%	1839

Other funds holding RARX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cubist Systematic Strategies's RARX Position: Q4 2019 in Review

Cubist Systematic Strategies sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q4 2019, closing a stake of 10,455 shares — an estimated $247K sold.

Cubist Systematic Strategies first reported a position in RARX in Q4 2017 and held it in 6 quarters. The position peaked at $558K in Q1 2019. 146 funds tracked by Wall St. Rank hold RARX as of Q4 2019.

Cubist Systematic Strategies reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Cubist Systematic Strategies sold 10,455 Ra Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $247K.
Cubist Systematic Strategies first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 6 quarters.
Cubist Systematic Strategies's Ra Pharmaceuticals, Inc. Common Stock position peaked at $558K in Q1 2019.
146 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Cubist Systematic Strategies's 13F filing for Q4 2019, filed 14 Feb 2020.